Last reviewed · How we verify

Steve Yoelin M.D. Medical Associates, Inc. — Portfolio Competitive Intelligence Brief

Steve Yoelin M.D. Medical Associates, Inc. pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. ATGC Co., Ltd. · 1 shared drug class
  2. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  3. Brigitte Schürch · 1 shared drug class
  4. Carruthers Dermatology Centre · 1 shared drug class
  5. Department of Medical Services Ministry of Public Health of Thailand · 1 shared drug class
  6. Galderma R&D · 1 shared drug class
  7. Huons Co., Ltd. · 1 shared drug class
  8. Innovaderm Research Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Steve Yoelin M.D. Medical Associates, Inc.:

Cite this brief

Drug Landscape (2026). Steve Yoelin M.D. Medical Associates, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/steve-yoelin-m-d-medical-associates-inc. Accessed 2026-05-17.

Related